How should performance in EBUS mediastinal staging in lung cancer be measured?

Matthew Evison; Philip Crosbie; Neal Navani; Matthew Callister; Robert C Rintoul; David Baldwin; Richard Booton

doi:10.1038/bjc.2016.253

How should performance in EBUS mediastinal staging in lung cancer be measured?

Matthew Evison, Philip Crosbie, Neal Navani, Matthew Callister, Robert C Rintoul, David Baldwin, Richard Booton

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	e9
Journal	British Journal of Cancer
Volume	115
Issue number	8
Early online date	23 Aug 2016
DOIs	https://doi.org/10.1038/bjc.2016.253
Publication status	Published - 11 Oct 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/bjc.2016.253

Cite this

@article{eb5a8eb43e9c4c5ca3d51f675559cf80,

title = "How should performance in EBUS mediastinal staging in lung cancer be measured?",

author = "Matthew Evison and Philip Crosbie and Neal Navani and Matthew Callister and Rintoul, \{Robert C\} and David Baldwin and Richard Booton",

year = "2016",

month = oct,

day = "11",

doi = "10.1038/bjc.2016.253",

language = "English",

volume = "115",

pages = "e9",

journal = "British Journal of Cancer",

issn = "0007-0920",